Portfolio company
Medium Biosciences
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops AI-designed protein affinity reagents for research teams and diagnostic developers to support target binding and detection.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Nabla Bio
This company develops generative artificial intelligence and high-throughput screening platforms to design therapeutic antibodies for pharmaceutical and biotechnology partners.
Aikium
This company develops artificial intelligence and synthetic biology platforms to design and screen protein therapeutic libraries for biotechnology and pharmaceutical partners.
PentaBind
This company develops aptamer-based therapeutics and sensing assets for pharmaceutical and diagnostics companies using a generative artificial intelligence and wet-lab platform.
Diffuse Bio
This company develops generative artificial intelligence software and experimental screening platforms for protein design and validation for pharmaceutical and biotechnology researchers.
Computational drug discovery platform
This company develops an AI-native platform for biologics discovery and engineering for biotechnology and pharmaceutical partners.
Xaira
The company develops artificial intelligence platforms to design and develop antibody-based medicines for patients with various diseases.
Open Protein
This company provides a no-code machine learning platform for protein engineering and sequence generation to researchers in biotechnology, pharmaceuticals and academia.
Micrographia Bio
This company develops AI-driven microscopy and spatial proteomics platforms to help drug developers and researchers visualise molecular interactions and identify therapeutic targets.